Esther Vazquez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7684814/publications.pdf

Version: 2024-02-01

61857 56606 7,976 161 43 83 citations h-index g-index papers 165 165 165 9484 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nanocomposite Hydrogels: 3D Polymer–Nanoparticle Synergies for On-Demand Drug Delivery. ACS Nano, 2015, 9, 4686-4697.	7.3	624
2	Promises, facts and challenges for graphene in biomedical applications. Chemical Society Reviews, 2017, 46, 4400-4416.	18.7	564
3	Safety Assessment of Graphene-Based Materials: Focus on Human Health and the Environment. ACS Nano, 2018, 12, 10582-10620.	7.3	438
4	Classification Framework for Grapheneâ€Based Materials. Angewandte Chemie - International Edition, 2014, 53, 7714-7718.	7.2	369
5	Microbial factories for recombinant pharmaceuticals. Microbial Cell Factories, 2009, 8, 17.	1.9	349
6	Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial Cell Factories, 2016, 15, 33.	1.9	265
7	Dispersibilityâ€Dependent Biodegradation of Graphene Oxide by Myeloperoxidase. Small, 2015, 11, 3985-3994.	5 . 2	215
8	TRPV4 channel is involved in the coupling of fluid viscosity changes to epithelial ciliary activity. Journal of Cell Biology, 2005, 168, 869-874.	2.3	199
9	Swelling-activated Ca2+ Entry via TRPV4 Channel Is Defective in Cystic Fibrosis Airway Epithelia. Journal of Biological Chemistry, 2004, 279, 54062-54068.	1.6	159
10	Bacterial inclusion bodies: making gold from waste. Trends in Biotechnology, 2012, 30, 65-70.	4.9	157
11	Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. Journal of Clinical Investigation, 2004, 113, 1032-1039.	3.9	155
12	Degradation of Singleâ€Layer and Fewâ€Layer Graphene by Neutrophil Myeloperoxidase. Angewandte Chemie - International Edition, 2018, 57, 11722-11727.	7.2	135
13	Bacterial Inclusion Bodies: Discovering Their Better Half. Trends in Biochemical Sciences, 2017, 42, 726-737.	3.7	134
14	Maxi K ⁺ channel mediates regulatory volume decrease response in a human bronchial epithelial cell line. American Journal of Physiology - Cell Physiology, 2002, 283, C1705-C1714.	2.1	99
15	Protein-Based Therapeutic Killing for Cancer Therapies. Trends in Biotechnology, 2018, 36, 318-335.	4.9	98
16	<i>In Vivo</i> Architectonic Stability of Fully <i>de Novo</i> Designed Protein-Only Nanoparticles. ACS Nano, 2014, 8, 4166-4176.	7.3	89
17	Graphene Improves the Biocompatibility of Polyacrylamide Hydrogels: 3D Polymeric Scaffolds for Neuronal Growth. Scientific Reports, 2017, 7, 10942.	1.6	87
18	Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends in Biotechnology, 2008, 26, 267-275.	4.9	85

#	Article	IF	CITATIONS
19	Protective Effect of the KCNMB1 E65K Genetic Polymorphism Against Diastolic Hypertension in Aging Women and Its Relevance to Cardiovascular Risk. Circulation Research, 2005, 97, 1360-1365.	2.0	78
20	Bacterial inclusion bodies are industrially exploitable amyloids. FEMS Microbiology Reviews, 2019, 43, 53-72.	3.9	77
21	Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial. Advanced Materials, 2009, 21, 4249-4253.	11.1	73
22	Nanostructured antimicrobial peptides: The last push towards clinics. Biotechnology Advances, 2020, 44, 107603.	6.0	71
23	The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials, 2010, 31, 5805-5812.	5.7	67
24	Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies. Advanced Materials, 2012, 24, 1742-1747.	11.1	67
25	Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials, 2012, 33, 8714-8722.	5.7	65
26	Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomaterialia, 2013, 9, 6134-6142.	4.1	65
27	Towards protein-based viral mimetics for cancer therapies. Trends in Biotechnology, 2015, 33, 253-258.	4.9	65
28	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Molecular Medicine, $2018,10,10$	3.3	64
29	Functional coupling of TRPV4 cationic channel and large conductance, calcium-dependent potassium channel in human bronchial epithelial cell lines. Pflugers Archiv European Journal of Physiology, 2008, 457, 149-159.	1.3	63
30	Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology, 2010, 21, 205101.	1.3	62
31	Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. International Journal of Nanomedicine, 2012, 7, 4533.	3.3	61
32	Bottomâ€Up Instructive Quality Control in the Biofabrication of Smart Protein Materials. Advanced Materials, 2015, 27, 7816-7822.	11.1	61
33	Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine, 2010, 5, 259-268.	1.7	59
34	Few‣ayer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients. Angewandte Chemie - International Edition, 2017, 56, 3014-3019.	7.2	59
35	Plasma Membrane Voltage-dependent Anion Channel Mediates Antiestrogen-activated Maxi Cl– Currents in C1300 Neuroblastoma Cells. Journal of Biological Chemistry, 2003, 278, 33284-33289.	1.6	57
36	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. Journal of Controlled Release, 2018, 274, 81-92.	4.8	55

#	Article	IF	Citations
37	Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microbial Cell Factories, 2012, 11, 76.	1.9	52
38	The progesterone receptor regulates the expression of TRPV4 channel. Pflugers Archiv European Journal of Physiology, 2009, 459, 105-113.	1.3	50
39	Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Critical Reviews in Biotechnology, 2015, 35, 209-221.	5.1	50
40	Assembly of histidine-rich protein materials controlled through divalent cations. Acta Biomaterialia, 2019, 83, 257-264.	4.1	49
41	Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells. Journal of Controlled Release, 2020, 320, 96-104.	4.8	48
42	Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microbial Cell Factories, 2011, 10, 101.	1.9	47
43	Graphene Oxide Upregulates the Homeostatic Functions of Primary Astrocytes and Modulates Astrocyte-to-Neuron Communication. Nano Letters, 2018, 18, 5827-5838.	4.5	47
44	Differential effects of graphene materials on the metabolism and function of human skin cells. Nanoscale, 2018, 10, 11604-11615.	2.8	44
45	Genetic variation in the KCNMA1 potassium channel \hat{l}_{\pm} subunit as risk factor for severe essential hypertension and myocardial infarction. Journal of Hypertension, 2008, 26, 2147-2153.	0.3	43
46	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB Journal, 2015, 29, 464-476.	0.2	43
47	Divalent Cations: A Molecular Glue for Protein Materials. Trends in Biochemical Sciences, 2020, 45, 992-1003.	3.7	42
48	Pattern of trkB protein-like immunoreactivity in vivo and the in vitro effects of brain-derived neurotrophic factor (BDNF) on developing cochlear and vestibular neurons. Anatomy and Embryology, 1994, 189, 157-67.	1.5	41
49	Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discovery Today, 2008, 13, 1067-1074.	3.2	41
50	Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine, 2012, 7, 79-93.	1.7	40
51	Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO ₂ -Expanded Solvents. Nano Letters, 2013, 13, 3766-3774.	4.5	40
52	Selective CXCR4 ⁺ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin. Small, 2018, 14, e1800665.	5 . 2	40
53	Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci. Advanced Materials, 2020, 32, e1907348.	11.1	40
54	Post-production protein stability: trouble beyond the cell factory. Microbial Cell Factories, 2011, 10, 60.	1.9	39

#	Article	IF	CITATIONS
55	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. Journal of Hematology and Oncology, 2020, 13, 36.	6.9	39
56	Modular Protein Engineering in Emerging Cancer Therapies. Current Pharmaceutical Design, 2009, 15, 893-916.	0.9	38
57	Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. International Journal of Pharmaceutics, 2014, 473, 286-295.	2.6	38
58	An Increase in Membrane Cholesterol by Graphene Oxide Disrupts Calcium Homeostasis in Primary Astrocytes. Small, 2019, 15, e1900147.	5.2	37
59	Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. Soft Matter, 2016, 12, 3451-3460.	1.2	36
60	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. Haematologica, 2020, 105, 741-753.	1.7	36
61	Artificial Inclusion Bodies for Clinical Development. Advanced Science, 2020, 7, 1902420.	5.6	36
62	A review of TRP channels splicing. Seminars in Cell and Developmental Biology, 2006, 17, 607-617.	2.3	35
63	Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. Acta Biomaterialia, 2014, 10, 1354-1359.	4.1	35
64	Insights on the emerging biotechnology of histidine-rich peptides. Biotechnology Advances, 2022, 54, 107817.	6.0	35
65	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer models. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1987-1996.	1.7	34
66	Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced Science, 2019, 6, 1900849.	5.6	34
67	Recombinant protein materials for bioengineering and nanomedicine. Nanomedicine, 2014, 9, 2817-2828.	1.7	33
68	Two-Dimensional Microscale Engineering of Protein-Based Nanoparticles for Cell Guidance. ACS Nano, 2013, 7, 4774-4784.	7.3	32
69	Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories, 2016, 15, 166.	1.9	32
70	Peptideâ€Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4 ⁺ Solid Tumors. Advanced Functional Materials, 2017, 27, 1700919.	7.8	32
71	Biodegradable Poly(vinyl alcohol)-polyethylenimine Nanocomposites for Enhanced Gene Expression In Vitro and In Vivo. Biomacromolecules, 2012, 13, 73-83.	2.6	31
72	Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach. Journal of Controlled Release, 2018, 279, 29-39.	4.8	30

#	Article	IF	Citations
73	Engineering building blocks for self-assembling protein nanoparticles. Microbial Cell Factories, 2010, 9, 101.	1.9	29
74	Murine CFTR Channel and its Role in Regulatory Volume Decrease of Small Intestine Crypts. Cellular Physiology and Biochemistry, 2000, 10, 321-328.	1.1	28
75	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports, 2016, 6, 35765.	1.6	28
76	Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 535-541.	1.7	27
77	Survival of inner ear sensory neurons in trk mutant mice. Mechanisms of Development, 1997, 64, 77-85.	1.7	26
78	A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine, 2013, 8, 1587-1599.	1.7	26
79	Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1241-1251.	1.7	26
80	Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. Acta Biomaterialia, 2017, 60, 256-263.	4.1	26
81	Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine, 2013, 8, 1895-1898.	1.7	25
82	Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine, 2014, 9, 207-220.	1.7	25
83	Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles. Pharmaceutics, 2020, 12, 1004.	2.0	25
84	Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology, 2017, 28, 015102.	1.3	24
85	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 49.	3.5	24
86	Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials, 2010, 31, 9333-9339.	5.7	22
87	Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. Journal of Controlled Release, 2013, 171, 63-72.	4.8	22
88	Selective delivery of T22-PE24-H6 to CXCR4 ⁺ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. Theranostics, 2020, 10, 5169-5180.	4.6	22
89	Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale, 2017, 9, 6427-6435.	2.8	21
90	Protein-driven nanomedicines in oncotherapy. Current Opinion in Pharmacology, 2019, 47, 1-7.	1.7	21

#	Article	IF	Citations
91	Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine, 2015, 10, 873-891.	1.7	20
92	Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine, 2016, 11, 1333-1336.	1.7	20
93	Conformational Conversion during Controlled Oligomerization into Nonamylogenic Protein Nanoparticles. Biomacromolecules, 2018, 19, 3788-3797.	2.6	18
94	Integrated approach to produce a recombinant, hisâ€ŧagged human αâ€galactosidase a in mammalian cells. Biotechnology Progress, 2011, 27, 1206-1217.	1.3	17
95	Engineering Protein Nanoparticles Out from Components of the Human Microbiome. Small, 2020, 16, 2001885.	5.2	17
96	Biofabrication of functional protein nanoparticles through simple His-tag engineering. ACS Sustainable Chemistry and Engineering, 2021, 9, 12341-12354.	3.2	17
97	RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1263-1266.	1.7	16
98	Keratinocytes are capable of selectively sensing low amounts of graphene-based materials: Implications for cutaneous applications. Carbon, 2020, 159, 598-610.	5.4	16
99	Release of functional fibroblast growth factor-2 from artificial inclusion bodies. Journal of Controlled Release, 2020, 327, 61-69.	4.8	16
100	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine, 2021, Volume 16, 1869-1888.	3.3	16
101	GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Delivery, 2022, 29, 1384-1397.	2.5	16
102	Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication, 2016, 8, 025001.	3.7	15
103	Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides. Science China Materials, 2020, 63, 644-653.	3.5	15
104	Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells. ACS Applied Materials & Samp; Interfaces, 2020, 12, 5381-5388.	4.0	15
105	Sublethal exposure of small few-layer graphene promotes metabolic alterations in human skin cells. Scientific Reports, 2020, 10, 18407.	1.6	15
106	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. Acta Pharmaceutica Sinica B, 2022, 12, 2578-2591.	5.7	15
107	Nanoparticulate architecture of protein-based artificial viruses is supported by protein–DNA interactions. Nanomedicine, 2011, 6, 1047-1061.	1.7	14
108	A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity. Acta Biomaterialia, 2020, 113, 584-596.	4.1	14

#	Article	IF	CITATIONS
109	Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. Acta Biomaterialia, 2021, 119, 312-322.	4.1	14
110	Analytical Approaches for Assessing Aggregation of Protein Biopharmaceuticals. Current Pharmaceutical Biotechnology, 2011, 12, 1530-1536.	0.9	13
111	Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microbial Cell Factories, 2016, 15, 59.	1.9	13
112	Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP. Acta Biomaterialia, 2020, 103, 272-280.	4.1	13
113	Engineering the Performance of Artificial Inclusion Bodies Built of Catalytic β-Galactosidase. ACS Sustainable Chemistry and Engineering, 2021, 9, 2552-2558.	3.2	13
114	In Vitro Fabrication of Microscale Secretory Granules. Advanced Functional Materials, 2021, 31, 2100914.	7.8	13
115	Protein Aggregation and Soluble Aggregate Formation Screened by a Fast Microdialysis Assay. Journal of Biomolecular Screening, 2010, 15, 453-457.	2.6	12
116	Engineering multifunctional protein nanoparticles by <i>in vitro</i> disassembling and reassembling of heterologous building blocks. Nanotechnology, 2017, 28, 505102.	1.3	12
117	Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1777-1786.	1.7	12
118	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials, 2022, 280, 121258.	5.7	12
119	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer. Acta Biomaterialia, 2019, 99, 426-432.	4.1	11
120	Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles. Science China Materials, 2019, 62, 892-898.	3.5	11
121	Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles. Nanotechnology, 2019, 30, 115101.	1.3	11
122	Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering. Science China Materials, 2020, 63, 147-156.	3.5	11
123	Stable anchoring of bacteria-based protein nanoparticles for surface enhanced cell guidance. Journal of Materials Chemistry B, 2020, 8, 5080-5088.	2.9	11
124	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers. Cancers, 2021, 13, 2929.	1.7	11
125	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. Journal of Controlled Release, 2021, 335, 117-129.	4.8	11
126	Expression of the cytoskeletal protein MAP5 and its regulation by neurotrophin 3 (NT3) in the inner ear sensory neurons. Anatomy and Embryology, 1997, 195, 299-310.	1.5	10

#	Article	IF	CITATIONS
127	Engineered Biological Entities for Drug Delivery and Gene Therapy. Progress in Molecular Biology and Translational Science, 2011, 104, 247-298.	0.9	10
128	CXCR4 ⁺ -targeted protein nanoparticles produced in the food-grade bacterium <i>Lactococcus lactis</i> . Nanomedicine, 2016, 11, 2387-2398.	1.7	10
129	Ion-dependent slow protein release from <i>inÂvivo</i> disintegrating micro-granules. Drug Delivery, 2021, 28, 2383-2391.	2.5	10
130	Protein nanoparticles are nontoxic, tuneable cell stressors. Nanomedicine, 2018, 13, 255-268.	1.7	9
131	Surface-Bound Gradient Deposition of Protein Nanoparticles for Cell Motility Studies. ACS Applied Materials & Samp; Interfaces, 2018, 10, 25779-25786.	4.0	9
132	Degradation of Singleâ€Layer and Fewâ€Layer Graphene by Neutrophil Myeloperoxidase. Angewandte Chemie, 2018, 130, 11896-11901.	1.6	9
133	Nanostructure Empowers Active Tumor Targeting in Ligandâ€Based Molecular Delivery. Particle and Particle Systems Characterization, 2019, 36, 1900304.	1.2	9
134	Engineering Protein Venoms as Selfâ€Assembling CXCR4â€Targeted Cytotoxic Nanoparticles. Particle and Particle Systems Characterization, 2020, 37, 2000040.	1.2	9
135	The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics, 2022, 14, 602.	2.0	9
136	Subcutaneous preconditioning increases invasion and metastatic dissemination in colorectal cancer models. DMM Disease Models and Mechanisms, 2014, 7, 387-96.	1.2	8
137	Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability. Materials Letters, 2015, 154, 140-143.	1.3	8
138	Few layer graphene does not affect the function and the autophagic activity of primary lymphocytes. Nanoscale, 2019, 11, 10493-10503.	2.8	8
139	Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Description (2011), 13, 29406-29415.	4.0	8
140	Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines. Acta Biomaterialia, 2021, 130, 211-222.	4.1	8
141	Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics, 2022, 14, 192.	2.0	8
142	Targeting in Cancer Therapies. Medical Sciences (Basel, Switzerland), 2016, 4, 6.	1.3	7
143	High-Throughput Cell Motility Studies on Surface-Bound Protein Nanoparticles with Diverse Structural and Compositional Characteristics. ACS Biomaterials Science and Engineering, 2019, 5, 5470-5480.	2.6	7
144	Efficient bioactive oligonucleotideâ€protein conjugation for cellâ€targeted cancer therapy. ChemistryOpen, 2019, 8, 382-387.	0.9	7

#	Article	IF	CITATIONS
145	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. Journal of Controlled Release, 2022, 343, 277-287.	4.8	7
146	Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14047.	1.8	6
147	Developing Protein–Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial Agents. ACS Applied Materials & Interfaces, 2020, 12, 57746-57756.	4.0	6
148	Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. Biomedicines, 2022, 10, 1680.	1.4	6
149	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics, 2021, 13, 1922.	2.0	5
150	A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. Pharmaceutics, 2022, 14, 887.	2.0	5
151	Developmental changes in nerve growth factor (NGF) binding and NGF receptor proteins trkA and p75 in the facial nerve. Anatomy and Embryology, 1994, 190, 73-85.	1.5	4
152	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. Biomedicine and Pharmacotherapy, 2022, 150, 112940.	2.5	4
153	An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. International Journal of Molecular Sciences, 2022, 23, 4958.	1.8	4
154	The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China Materials, 2022, 65, 1662-1670.	3.5	3
155	SERS-Based Methodology for the Quantification of Ultratrace Graphene Oxide in Water Samples. Environmental Science & Environmental Science & Environme	4.6	3
156	Dialysis: A Characterization Method of Aggregation Tendency. Methods in Molecular Biology, 2015, 1258, 321-330.	0.4	2
157	Targeting low-density lipoprotein receptors with protein-only nanoparticles. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	2
158	Improved performance of proteinâ€based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnology Progress, 2013, 29, 1458-1463.	1.3	1
159	Swelling-Activated Calcium-Dependent Potassium Channels In Airway Epithelial Cells. , 2004, , 388-389.		0
160	Nanopills: Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies (Adv. Mater. 13/2012). Advanced Materials, 2012, 24, 1741-1741.	11.1	0
161	Polylactide, Processed by a Foaming Method Using Compressed Freon R134a, for Tissue Engineering. Polymers, 2021, 13, 3453.	2.0	0